CN117045615A - Liquid capsule for treating lung cancer and preparation method thereof - Google Patents

Liquid capsule for treating lung cancer and preparation method thereof Download PDF

Info

Publication number
CN117045615A
CN117045615A CN202311232555.4A CN202311232555A CN117045615A CN 117045615 A CN117045615 A CN 117045615A CN 202311232555 A CN202311232555 A CN 202311232555A CN 117045615 A CN117045615 A CN 117045615A
Authority
CN
China
Prior art keywords
parts
liquid capsule
capsule
lung cancer
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202311232555.4A
Other languages
Chinese (zh)
Inventor
李戈
杨阳
刘浩
赵岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Traditional Chinese Medicine Hospital
Original Assignee
Dalian Traditional Chinese Medicine Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Traditional Chinese Medicine Hospital filed Critical Dalian Traditional Chinese Medicine Hospital
Priority to CN202311232555.4A priority Critical patent/CN117045615A/en
Publication of CN117045615A publication Critical patent/CN117045615A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/342—Adenophora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8884—Arisaema, e.g. Jack in the pulpit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of biological medicine, and particularly discloses a liquid capsule for treating lung cancer and a preparation method thereof, wherein the liquid capsule comprises a liquid capsule content and a capsule material of the liquid capsule, the liquid capsule content is prepared from the following raw materials, by weight, 500 parts of astragalus mongholicus, 150 parts of bighead atractylodes rhizome, 150 parts of poria cocos, 150 parts of dwarf lilyturf tuber, 150 parts of adenophora root, 150 parts of herba selaginellae, 150 parts of jaundice, 150 parts of tartary buckwheat, 150 parts of chicken's gizzard-skin, 18-22 parts of polyethylene glycol 400 and 0.15-0.25 part of glycerol.

Description

Liquid capsule for treating lung cancer and preparation method thereof
Technical Field
The invention belongs to the technical field of biological medicines, and in particular relates to a liquid capsule for treating lung cancer and a preparation method thereof.
Background
Lung cancer, or bronchogenic carcinoma, originates from the bronchial mucosa and is the most common primary malignancy of the lung. The etiology of lung cancer is not completely clear so far, and a large amount of data show that a large amount of long-term smoking has a very close relationship with the occurrence of lung cancer. Existing studies have demonstrated that: the probability of lung cancer of a large number of smokers in a long period is 10-20 times that of non-smokers, and the smaller the smoking starting age, the higher the probability of lung cancer. In addition, smoking not only directly affects the physical health of the smoker, but also has adverse effects on the health of surrounding people, so that the lung cancer prevalence of the passive smoker is obviously increased. Urban resident lung cancer has a higher incidence than rural areas, which may be related to urban atmospheric pollution and the presence of carcinogens in smoke.
Symptoms of lung cancer are broadly divided into: local symptoms, systemic symptoms, extrapulmonary symptoms, infiltration, and metastasis symptoms. At present, the treatment of lung cancer at home and abroad mainly comprises operations, radiotherapy and chemotherapy, but the methods are easy to cause larger side effects on normal organs of patients, and the prognosis and survival rate of the patients are poor. Traditional Chinese medicines are increasingly valued in the field of tumor treatment by virtue of the characteristics of effectiveness and low toxicity. The traditional Chinese medicine considers that the pathogenesis of cancer (malignant tumor) is complicated, but the reasons are not limited to the external factor and the internal factor, the external factor is qi with six improper symptoms, and the internal factor is seven-emotion stimulation and deficiency of healthy qi. Due to pathogenic factors, damp, turbid, toxic, blood stasis, deficiency and the like are mutually intersected to cause cancer.
The treatment of cancer firstly eliminates pathogenic factors (removing dampness, eliminating turbid pathogen, detoxication and removing blood stasis) so as to achieve the aim of eliminating cancer; secondly, strengthening the body resistance is an important key for treating cancers. The new traditional Chinese medicine for treating lung cancer on the market in recent years is Kanglite capsules, and has the effects of tonifying qi and nourishing yin, and reducing swelling and resolving masses; the compound yew capsules have the effects of removing blood stasis and resolving masses; the Zilongjin tablet has the effects of tonifying qi and nourishing blood, clearing heat and detoxicating, regulating qi and resolving phlegm; cinobufagin tablet has the functions of detoxication, detumescence and pain relief; ginseng-Yi capsule has the effects of strengthening body resistance, nourishing primordial qi and blood.
All the above medicines have certain curative effects, but the core pathogenesis (damp, turbid, toxic, stasis and deficiency) of the cancer is not fully considered, so that the prescription is required to have curative effects, and is also required to be developed aiming at the cause of disease and taking the whole new medicine, and the traditional Chinese medicine decoction at present has the defects of decoction, inconvenience in carrying and taking, poor taste and the like.
Disclosure of Invention
The invention aims to provide a liquid capsule for treating lung cancer and a preparation method thereof, which are used for solving the problems in the background technology.
In order to achieve the above purpose, the present invention provides the following technical solutions:
the liquid capsule for treating lung cancer comprises liquid capsule contents and capsule wall materials of the liquid capsule, wherein the liquid capsule contents are prepared from the following raw materials, by weight, 500 parts of astragalus membranaceus, 150 parts of bighead atractylodes rhizome, 150 parts of poria cocos, 150 parts of radix ophiopogonis, 150 parts of radix adenophorae, 150 parts of herba lycopodii, 150 parts of herba selaginellae chinensis, 150 parts of snake six-cereal, 150 parts of wild buckwheat rhizome, 150 parts of endothelium corneum gigeriae galli, 40018-22 parts of polyethylene glycol and 0.15-0.25 part of glycerol, and the capsule wall materials of the liquid capsule are prepared from the following raw materials, by weight, 90-110 parts of gelatin, 30-50 parts of glycerol and 110-130 parts of water.
Preferably, the covering part of the liquid capsule is coated with annular sealing material.
A method for preparing a liquid capsule for treating lung cancer, which is characterized by comprising the following steps:
s1, selecting proper amounts of raw astragalus, bighead atractylodes rhizome, poria cocos, dwarf lilyturf tuber, adenophora root, herba lycopodii, herba selaginellae chinensis, six grains of snake, golden buckwheat rhizome and chicken' S gizzard-membrane, adding 8 times of 70% ethanol, heating and reflux-extracting for 3 times, extracting for 3 hours each time, filtering the extracting solution, merging the extracting solutions, recovering the ethanol, and concentrating under reduced pressure until no alcohol smell exists, thus obtaining concentrated solution.
S2, purifying an extract: taking the concentrated solution in the step S1 as a sample, and adsorbing by using macroporous adsorption resin D101, wherein the following medicinal materials are prepared: eluting with 10% ethanol at a mass ratio of 1.3:1, eluting with 70% ethanol, collecting eluate, recovering ethanol, drying under reduced pressure, and pulverizing into fine powder.
S3, preparing the content of the liquid capsule: adding the extract fine powder in the step S2 into polyethylene glycol and glycerol mixed solution preheated to 60 ℃, uniformly stirring, grinding for 3 times by a colloid mill, and then placing into a liquid preparation tank for continuous stirring for standby.
And S4, adding glycerol, gelatin and water into a gelatin dissolving tank according to a capsule material formula, heating and stirring, keeping the temperature at 75-80 ℃ after the gelatin is melted, sieving with a 60-mesh sieve, and keeping the temperature of the obtained gelatin solution at 55-60 ℃ for later use.
S5, pressing the content in the S3 and the glue solution in the S4 into liquid capsules by using a liquid capsule machine to obtain the finished product.
Preferably, the technological parameter of the reduced pressure concentration in the step S1 is vacuum degree of 0.09-0.10Mpa and temperature of 50-65 ℃.
Preferably, the eluting volume of 70% ethanol in the S2 is 8-10BV, the technological parameters of decompression drying are vacuum degree 0.09-0.10Mpa, the temperature is 60-65 ℃, and the extract is crushed and sieved by a 80-100 mesh sieve after being dried.
Compared with the prior art, the invention has the beneficial effects that:
according to the liquid capsule for treating lung cancer and the preparation method thereof, ten traditional Chinese medicine materials are combined, extracted and purified, the polyethylene glycol and glycerol mixed solution is adopted as a suspending agent, and glycerol, gelatin and water in a certain proportion are adopted as capsule materials of the liquid capsule to prepare the liquid capsule for treating lung cancer, and the liquid capsule is prepared by a modern medicament means, is accurate and quantitative, has high bioavailability, has the characteristics of neat appearance, high disintegration speed, simultaneous treatment of symptoms and root causes, mild medicament property and convenient administration, effectively masks the bad smell and bitter taste of the traditional Chinese medicine, improves the compliance of patients, and is suitable for long-term administration of patients.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The invention relates to a herbal preparation, which comprises the following components:
the radix astragali is dried root of Astragalus mongholicus bge or Astragalus membranaceus bge. Its medicinal herbs are sweet and slightly warm. Has effects in invigorating qi, invigorating yang, strengthening body resistance, inducing diuresis, relieving edema, promoting salivation, nourishing blood, removing stagnation, relieving arthralgia, removing toxic materials, expelling pus, healing sore, and promoting granulation. The product mainly contains triterpene saponin components: astragaloside I, II, III, IV (astragaloside IV), capsular Astragaloside I, II, etc.; flavonoid components: formononetin, calycosin glucoside, etc.; also contains polysaccharide, amino acid, etc. The Chinese pharmacopoeia specifies that the product contains calycosin glucoside not less than 0.020% and decoction pieces not less than 0.020%; astragaloside IV is not less than 0.080%, and decoction pieces are not less than 0.080%. The radix astragali Preparata contains astragaloside IV not less than 0.060%, and calycosin glucoside not less than 0.020%. Pharmacological action: the astragalus polysaccharide can promote the synthesis of RNA and protein, make the cell grow vigorously, prolong the service life, and resist fatigue, low temperature and influenza virus. The water decoction, polysaccharide and saponin of radix astragali have effects of protecting and promoting hematopoiesis. The total saponins of radix astragali have positive inotropic effect, and the total flavonoids and total saponins of radix astragali can protect ischemic and anoxic cardiac muscle. The radix astragali water decoction has kidney protecting, urine protein eliminating and diuretic effects, and has bidirectional regulating effect on blood pressure. In addition, radix astragali has effects of resisting aging, resisting radiation, relieving inflammation, reducing blood lipid, lowering blood sugar, enhancing immunity, resisting tumor, protecting liver, etc.
The Atractylodis rhizoma is dry rhizome of Atractylodis rhizoma of Compositae. Its medicinal herbs are sweet and bitter and warm. Has effects of invigorating qi and spleen, eliminating dampness, promoting diuresis, relieving sweat, and preventing miscarriage. The product mainly contains volatile oils such as atractylone, atractylol ether, du Songnao, atractylenolide, etc., and lactone compounds such as atractylenolide I-IV, atractylenolide, etc. The product also contains fructose, inulin, atractylodis rhizoma polysaccharide, various amino acids, atractylodis rhizoma triol, and vitamin A. Pharmacological action: the Atractylodis rhizoma water decoction can promote gastric emptying and small intestine propulsion of mice, and can be used for preventing and treating experimental gastric ulcer. The atractylenolide I has effects of enhancing salivary amylase activity, promoting nutrient absorption, and regulating gastrointestinal function. Both the decoction and the fluid extract of the bighead atractylodes rhizome have obvious and durable diuretic effect. The Atractylodis rhizoma polysaccharide and Atractylodis rhizoma volatile oil can enhance cell immunity. The Atractylodis rhizoma water decoction has antiaging effect. The Atractylodis rhizoma ethanol extract and petroleum ether extract can inhibit the contraction of uterus smooth muscle of experimental animal. In addition, atractylodis rhizoma has effects of protecting liver, promoting bile flow, lowering blood sugar, resisting bacteria and tumor, tranquilizing, relieving cough, eliminating phlegm, etc.
Poria is dried sclerotium of Poria cocos (Roxb.) wolf belonging to Polyporaceae. Its medicinal herbs are sweet and light in taste and flat. It enters heart, lung, spleen and kidney meridians. Has effects of promoting diuresis, removing dampness, invigorating spleen, and tranquilizing mind. The product mainly contains polysaccharide, with the highest content of B-pachyman; triterpene component: pachymic acid, temoic acid, mesoporous acid, and the like; sterol component: ergosterol, and the like. The product also contains protein, fat, lecithin, adenine, etc. Pharmacological action: poria cocos decoction, syrup, alcohol extract and diethyl ether extract have the effects of promoting urination, tranquilizing mind, resisting tumor and increasing myocardial contractility. Pachyman has immunity enhancing effect. The product also has liver protecting, blood sugar lowering, antiaging, and gastric ulcer preventing effects.
The radix Ophiopogonis is dried root tuber of radix Ophiopogonis of Liliaceae. It is sweet in flavor, slightly bitter and slightly cold. Has effects of nourishing yin, moistening lung, invigorating stomach, promoting salivation, clearing heart fire, and relieving restlessness. The product mainly contains saponins: ophiopogonin B, D, etc.; high isoflavone component: methyl ophiopogon root flavanone A, B. The product also contains various amino acids, microelements, vitamin A-like substances, polysaccharide, etc. The total saponins of radix Ophiopogonis in the Chinese pharmacopoeia is not less than 0.12% calculated by rusi-keside aglycone. Pharmacological action: radix Ophiopogonis can enhance phagocytic capacity of reticuloendothelial system, and increase peripheral leukocyte; the ophiopogon japonicus polysaccharide can promote humoral immunity and cellular immunity, induce various cytokines and play an anticancer role by enhancing immune function; the ophiopogon polysaccharide has the anti-hypoxia protection effect on cerebral ischemia injury; radix Ophiopogonis can enhance pituitary adrenal cortex system effect and improve organism adaptability; the ophiopogon root total saponins have the effects of resisting arrhythmia, improving myocardial contractility, improving left ventricular function and resisting shock; the ophiopogon polysaccharide and the total saponins have the function of reducing blood sugar, and the ophiopogon saponin has obvious anti-inflammatory activity; the radix Ophiopogonis water decoction also has effects of tranquilizing, hypnotizing, improving blood rheological property and anticoagulation.
Radix Glehniae is dry root of Umbelliferae plant herba Coralli Glabrae. It is sweet in flavor, slightly bitter and slightly cold. Has effects of nourishing yin, clearing lung-heat, invigorating stomach, and promoting salivation. The product mainly contains polysaccharide, coumarin glycoside, polyacetylene, flavonoid, fatty acid, etc. Pharmacological action: the radix Glehniae polysaccharide has effects of inhibiting humoral and cellular immunity, and reducing blood sugar. The 50% methanol extract of glehnia root has obvious inhibition effect on tyrosinase activity. The ethanol extract has protective effect on acute liver injury. Coumarin and polyacetylene have antibacterial, antifungal, tranquilizing, and analgesic effects. The positive inhibition activity of the polyacetylene component Facaline glycol on EB virus is also enhanced by 10 times. The radix Glehniae water extract has inhibiting effect on various cancer cells. The water extract and the alcohol extract of the glehnia root have obvious anti-mutation effect. The linear furocoumarin has obvious anticancer effect, wherein the inhibition effect of imperatorin and isoimperatorin is strongest.
The rhizoma Fagopyri Dibotryis is dried rhizome of rhizoma Fagopyri Dibotryis of Polygonaceae. Its medicinal herbs are slightly pungent and astringent and cool. Enter lung meridian. Has effects of clearing heat, detoxicating, expelling pus and removing blood stasis. The product mainly contains flavonoids: hyperin, epicatechin, quercetin, and the like; terpenes: barytrenone, alditol; organic acid: syringic acid, succinic acid. The product also contains volatile oil, emodin anthraquinone component, etc. The Chinese pharmacopoeia prescribes that the medicinal material contains epicatechin not less than 0.030% and decoction pieces not less than 0.020%. Pharmacological action: the product has expectorant, antipyretic, antibacterial, antiinflammatory, antitumor, immunity regulating, blood sugar lowering, blood lipid reducing, platelet aggregation resisting, and antioxidant effects.
The endothelium corneum Gigeriae Galli is inner wall of dry sand bag of pheasant. It is sweet and flat in taste. Enter spleen, stomach, small intestine and bladder meridians. Has effects of invigorating stomach, resolving food stagnation, astringing essence, relieving seminal emission, treating stranguria, and removing calculus. The endothelium corneum Gigeriae Galli contains gastric hormone, keratin, trace pepsin, amylase, vitamins, trace elements, amino acids, etc. Pharmacological action: after the chicken's gizzard-membrane powder is orally taken, gastric secretion, acidity and digestibility are all improved, the gastric motility function is obviously enhanced, and the gastric emptying rate is accelerated. In vitro experiments prove that the product can enhance the activity of pepsin and pancreatic lipase. Animal experiments prove that the product can strengthen the contraction capacity of the sphincter vesica, reduce the urine volume and improve the consciousness.
The dry aerial parts of Salvia chinensis of Salvia of Labiatae are found. It is bitter, pungent and flat in nature and enters stomach, liver and lung meridians. Has effects of clearing heat and detoxicating, promoting blood circulation, activating qi-flowing, and relieving pain. It is mainly used for treating dysphagia, phlegm asthma, hepatitis, leucorrhea with red and white discharge, carbuncle, swelling, scrofula, etc. At present, the literature reports that chemical components separated from the lithospermum through mainly comprise polysaccharides, terpenes, sterols, polyphenols and the like. In recent years, the composition is widely applied to treating diseases such as tumor, hepatitis, gastritis, gynaecology and the like, particularly in the treatment of malignant tumors, and a plurality of doctors can dialectically apply the composition to the skin, so that good effects are obtained.
Herba Selaginellae Doederleinii is whole plant of Selaginella moellendorffii (Thunb.) Makino of Selaginella, and also called Selaginella moellendorffii, platycladus orientalis, and herba Odoniae Davidii. It is sweet and bitter; it is cool in nature. Has effects of promoting blood circulation, dispelling blood stasis, clearing away heat and toxic materials, dispelling pathogenic wind, removing dampness, relieving cough, stopping bleeding, etc. Herba Selaginellae Doederleinii contains flavonoids, alkaloids, lignans, etc. It is commonly used for treating cancer, laryngopharynx swelling and pain, cough due to lung heat, mastitis, and hemorrhage.
The snake six-cereal konjak has the characteristics of pungent and warm taste, has the effects of resolving phlegm, resolving masses, removing stasis, relieving swelling and the like, is tubers of perennial herbaceous plants of konjak genus of Araceae family, has the main chemical component of konjak glucomannan, and is one of characteristic medicinal materials for treating tumors. Can be used for treating peptic ulcer and gastritis. In the formula, the sophora fruit, the pseudo-ginseng and the aloe are taken as main medicines.
Embodiment one:
the liquid capsule content of the embodiment is prepared from the following raw materials, by weight, 500 parts of astragalus mongholicus, 150 parts of bighead atractylodes rhizome, 150 parts of poria cocos, 150 parts of radix ophiopogonis, 150 parts of adenophora stricta, 150 parts of herba lycopodii, 150 parts of herba selaginellae chinensis, 150 parts of snake six-cereal, 150 parts of wild buckwheat rhizome, 150 parts of endothelium corneum gigeriae galli, 18 parts of polyethylene glycol 400 and 0.15 part of glycerol, wherein the capsule wall material of the liquid capsule consists of the following raw materials, by weight, 90 parts of gelatin, 30 parts of glycerol and 110 parts of water.
The preparation method comprises the following steps:
firstly selecting proper amount of raw astragalus, bighead atractylodes rhizome, poria cocos, dwarf lilyturf tuber, adenophora root, herba lycopodii, herba selaginellae chinensis, six snakegourd grains, golden buckwheat rhizome and chicken's gizzard-membrane, adding 8 times of 70% ethanol, heating and reflux-extracting for 3 times, extracting for 3 hours each time, filtering the extracting solution, merging the extracting solution, recovering the ethanol, and concentrating under reduced pressure until no alcohol smell exists, thus obtaining concentrated solution. Then the concentrated solution is used as a sample, and is adsorbed by macroporous adsorption resin D101, wherein the following medicinal materials are used: the mass ratio of the resin is 1.3:1, then the resin is eluted by 10 percent ethanol, the eluent is washed off, then 70 percent ethanol is used for eluting, the eluent is collected, the ethanol is recovered, the decompression drying is carried out, and the extract fine powder is obtained after the pulverization into fine powder for standby use: adding the extract fine powder into polyethylene glycol and glycerol mixed solution preheated to 60 ℃, uniformly stirring, grinding for 3 times by a colloid mill, and then placing into a liquid preparation tank for continuous stirring for standby.
Preparing a capsule wall material, adding glycerol, gelatin and water into a gelatin dissolving tank according to a capsule wall material formula, heating and stirring, keeping the temperature at 75-80 ℃ after the gelatin is melted, sieving with a 60-mesh sieve, and keeping the obtained gelatin solution at 55-60 ℃ for later use.
Finally, the capsule content and the capsule glue solution are pressed into liquid capsules by a liquid capsule machine, wherein the process parameters of the decompression concentration of the liquid capsule content are 0.09-0.10Mpa in vacuum degree and 50-65 ℃, the elution volume by using 70% ethanol is 8-10BV, the process parameters of the decompression drying are 0.09-0.10Mpa in vacuum degree and 60-65 ℃, and the extract is crushed and sieved by a 80-100-mesh sieve after being dried.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (5)

1. The liquid capsule for treating the lung cancer is characterized by comprising a liquid capsule content and a capsule wall material of the liquid capsule, wherein the liquid capsule content is prepared from the following raw materials, by weight, 500 parts of astragalus mongholicus, 150 parts of bighead atractylodes rhizome, 150 parts of poria cocos, 150 parts of radix ophiopogonis, 150 parts of radix adenophorae, 150 parts of herba lycopodii, 150 parts of herba selaginellae chinensis, 150 parts of snake six-cereal, 150 parts of wild buckwheat rhizome, 150 parts of endothelium corneum gigeriae galli, 18-22 parts of polyethylene glycol 400 and 0.15-0.25 part of glycerol, and the capsule wall material of the liquid capsule is prepared from the following raw materials, by weight, 90-110 parts of gelatin, 30-50 parts of glycerol and 110-130 parts of water.
2. A liquid capsule for treating lung cancer according to claim 1, wherein: the sleeving part of the liquid capsule is coated with an annular sealing material.
3. A method for preparing a liquid capsule for treating lung cancer according to any one of claims 1-2, comprising the steps of:
s1, selecting proper amounts of raw astragalus, bighead atractylodes rhizome, poria cocos, dwarf lilyturf tuber, adenophora root, herba lycopodii, herba selaginellae chinensis, six grains of snake, golden buckwheat rhizome and chicken' S gizzard-membrane, adding 8 times of 70% ethanol, heating and reflux-extracting for 3 times, extracting for 3 hours each time, filtering the extracting solution, merging the extracting solutions, recovering the ethanol, and concentrating under reduced pressure until no alcohol smell exists, thus obtaining concentrated solution.
S2, purifying an extract: taking the concentrated solution in the step S1 as a sample, and adsorbing by using macroporous adsorption resin D101, wherein the following medicinal materials are prepared: eluting with 10% ethanol at a mass ratio of 1.3:1, eluting with 70% ethanol, collecting eluate, recovering ethanol, drying under reduced pressure, and pulverizing into fine powder.
S3, preparing the content of the liquid capsule: adding the extract fine powder in the step S2 into polyethylene glycol and glycerol mixed solution preheated to 60 ℃, uniformly stirring, grinding for 3 times by a colloid mill, and then placing into a liquid preparation tank for continuous stirring for standby.
And S4, adding glycerol, gelatin and water into a gelatin dissolving tank according to a capsule material formula, heating and stirring, keeping the temperature at 75-80 ℃ after the gelatin is melted, sieving with a 60-mesh sieve, and keeping the temperature of the obtained gelatin solution at 55-60 ℃ for later use.
S5, pressing the content in the S3 and the glue solution in the S4 into liquid capsules by using a liquid capsule machine to obtain the finished product.
4. A method for preparing a liquid capsule for treating lung cancer according to claim 3, wherein: the technological parameters of the reduced pressure concentration in the S1 are that the vacuum degree is 0.09-0.10Mpa, and the temperature is 50-65 ℃.
5. The liquid capsule for treating lung cancer and the preparation method thereof according to claim 3, wherein: the eluting volume of 70% ethanol in S2 is 8-10BV, the technological parameters of decompression drying are vacuum degree 0.09-0.10Mpa, the temperature is 60-65 ℃, and the extract is crushed and sieved by a 80-100 mesh sieve after drying.
CN202311232555.4A 2023-09-22 2023-09-22 Liquid capsule for treating lung cancer and preparation method thereof Withdrawn CN117045615A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311232555.4A CN117045615A (en) 2023-09-22 2023-09-22 Liquid capsule for treating lung cancer and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311232555.4A CN117045615A (en) 2023-09-22 2023-09-22 Liquid capsule for treating lung cancer and preparation method thereof

Publications (1)

Publication Number Publication Date
CN117045615A true CN117045615A (en) 2023-11-14

Family

ID=88655638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311232555.4A Withdrawn CN117045615A (en) 2023-09-22 2023-09-22 Liquid capsule for treating lung cancer and preparation method thereof

Country Status (1)

Country Link
CN (1) CN117045615A (en)

Similar Documents

Publication Publication Date Title
CN103961521A (en) Traditional Chinese medicine composition for treating aplastic anemia and preparation method
CN105918946B (en) Jujube-wolfberry liver-nourishing composition, granules and preparation method thereof
CN102247479B (en) Antitumor strong medicine and preparation method thereof
CN111437378B (en) Traditional Chinese medicine composition and medicine for preventing and treating chronic heart failure and preparation method thereof
CN105106307A (en) Traditional Chinese medicine composition for treating prostate cancer, and preparation method and application of traditional Chinese medicine composition
CN110339276B (en) Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof
CN106109521A (en) A kind of Radix Notoginseng oral liquid
CN106215118A (en) Antineoplastic health preparation and preparation method thereof
CN105395842A (en) Traditional Chinese medicine composition for treating diabetes and oral preparation and preparation method thereof
CN108893246A (en) A kind of Dendrobium officinale alcohol and preparation method thereof
CN117045615A (en) Liquid capsule for treating lung cancer and preparation method thereof
CN101816745B (en) Chinese medicine composite applicable to treating ascitesduetocirrhosis and preparation method thereof
CN115414441A (en) Traditional Chinese medicine composition with effects of nourishing blood, regulating menstruation, removing blood stasis and removing ecchymoses as well as preparation method and application thereof
CN114522213A (en) Herbal atomized composition for improving memory and preparation method thereof
CN113797294A (en) Medicine composition for treating atrophic gastritis and preparation method thereof
CN107952036B (en) Traditional Chinese medicine preparation for reducing blood sugar and preparation method thereof
CN111956715A (en) Medicine for treating alcoholic liver disease and preparation method thereof
CN111617135A (en) A Chinese medicinal composition for treating senile dementia of early and middle stages, and its preparation method
CN113018330A (en) Chinese patent medicine granules for treating cold and preparation method thereof
CN1085439A (en) A kind of anticancer herbal drug
CN104825818A (en) Traditional Chinese medicine for treating asthma
CN114796417B (en) Blood sugar reducing traditional Chinese medicine formula and preparation method thereof
CN114558086B (en) An oral Chinese medicinal composition for the treatment of eczema
CN114848764B (en) Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof
CN111195299B (en) Chinese medicinal composition for treating hepatic fibrosis and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20231114